Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERMAID Phase II study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea
jRCTs031190154Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Modality
- Small Molecules, Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trimebutine, Lactasin and abemaciclib in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Incidence of Grade 2 or higher diarrhea within 28 days. Started Dec 2019; status: completed.
02
Drugs
trimebutineLactasinabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs031190154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190154.